Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine

Busulfan combined with cyclophosphamide (BuCy) has long been considered a standard myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (HCT), including both nonmalignant conditions and myeloid diseases. Substituting fludarabine for cyclophosphamide (BuFlu) to reduce...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Harris, Andrew C., Boelens, Jaap J., Ahn, Kwang Woo, Fei, Mingwei, Abraham, Allistair, Artz, Andrew, Dvorak, Christopher, Frangoul, Haydar, Freytes, Cesar, Gale, Robert Peter, Hong, Sanghee, Lazarus, Hillard M., Loren, Alison, Mineishi, Shin, Nishihori, Taiga, O’Brien, Tracey, Williams, Kirsten, Pasquini, Marcelo C., Levine, John E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Transplantation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5998928/
https://ncbi.nlm.nih.gov/pubmed/29844205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016956
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares